NYSEMKT: ARMP
Armata Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their ARMP stock forecasts and price targets.

Forecast return on equity

Is ARMP forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is ARMP forecast to generate an efficient return on assets?

Company
-33.95%
Industry
11.37%
ARMP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ARMP earnings per share forecast

What is ARMP's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.57
Avg 2 year Forecast
-$0.84

ARMP revenue forecast

What is ARMP's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$5.4M+337.73%
Avg 2 year Forecast
$0.0-100%
ARMP's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ARMP revenue growth forecast

How is ARMP forecast to perform vs Biotechnology companies and vs the US market?

Company
337.73%
Industry
9,448.78%
Market
1,432.68%
ARMP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ARMP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ARMP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ARMP$6.16N/AN/A
VYGR$4.00$16.50+312.50%Buy
EDIT$2.34$5.00+113.68%Buy
ACHV$4.32$15.50+258.80%Buy
CABA$2.39$14.60+510.88%Strong Buy

Armata Pharmaceuticals Stock Forecast FAQ

What is ARMP's earnings growth forecast for 2025-2026?

(NYSEMKT: ARMP) Armata Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 203.21%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,932.28%.

Armata Pharmaceuticals's earnings in 2025 is -$46,901,000.On average, 3 Wall Street analysts forecast ARMP's earnings for 2025 to be -$57,066,916, with the lowest ARMP earnings forecast at -$54,828,998, and the highest ARMP earnings forecast at -$58,745,355.

In 2026, ARMP is forecast to generate -$30,386,280 in earnings, with the lowest earnings forecast at -$29,194,661 and the highest earnings forecast at -$31,279,994.

If you're new to stock investing, here's how to buy Armata Pharmaceuticals stock.

What is ARMP's revenue growth forecast for 2025-2026?

(NYSEMKT: ARMP) Armata Pharmaceuticals's forecast annual revenue growth rate of 337.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 9,448.78%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,432.68%.

Armata Pharmaceuticals's revenue in 2025 is $1,235,000.On average, 3 Wall Street analysts forecast ARMP's revenue for 2025 to be $196,399,126, with the lowest ARMP revenue forecast at $188,697,199, and the highest ARMP revenue forecast at $202,175,571.

In 2026, ARMP is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ARMP's forecast return on assets (ROA) for 2025-2026?

(NYSEMKT: ARMP) forecast ROA is -33.95%, which is lower than the forecast US Biotechnology industry average of 11.37%.

What is ARMP's Earnings Per Share (EPS) forecast for 2025-2026?

(NYSEMKT: ARMP) Armata Pharmaceuticals's current Earnings Per Share (EPS) is -$1.29. On average, analysts forecast that ARMP's EPS will be -$1.57 for 2025, with the lowest EPS forecast at -$1.51, and the highest EPS forecast at -$1.62. In 2026, ARMP's EPS is forecast to hit -$0.84 (min: -$0.80, max: -$0.86).

What is ARMP's forecast return on equity (ROE) for 2025-2026?

(NYSEMKT: ARMP) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.